Electrophysiological Evaluation of Visual Hallucination in Parkinson’s Disease Psychosis
Objective: Our understanding of the psychosis in Parkinson’s disease (PDPsy) is incomplete, and standard of care treatment with antipsychotics has its limitations. Neuroimaging and histopathology in PDPsy reveal that visual hallucinations (VHs), the hallmark of psychosis in PDPsy, arise…Parkinson disease psychosis: A systematic review and meta-analysis
Objective: To determine the prevalence of Parkinson disease psychosis (PDP) as a function of several putative risk factors: PD duration, age, cognitive impairment, dopaminergic or…Impact of Foslevodopa/Foscarbidopa Continuous Subcutaneous Infusion on Neuropsychiatric Symptoms in Clinical Practice: A Multicenter Study
Objective: To determine the incidence and risk factors of neuropsychiatric adverse events (AEs) in patients with Parkinson’s disease (PD) treated with foslevodopa/foscarbidopa continuous subcutaneous infusion…Severity of Psychotic Symptoms Is Independently Associated with Caregiver Burden in Parkinson’s Disease: A Cross-Sectional Analysis
Objective: To evaluate the association between psychotic symptom severity and caregiver burden in patients with PD. Background: Psychotic symptoms are common in Parkinson’s disease (PD)…Depression and Psychosis in military Veterans with Parkinson’s Disease (PD)
Objective: To compare the presence of co-morbid depression in groups of PD Veterans, with and without psychosis. Background: Depression and psychosis are important non motor…Delayed Parkinsonism in Anti‑NMDAR Encephalitis Following Immunotherapy – A Rare Clinical Manifestation
Objective: To describe a rare case of delayed parkinsonism emerging during the recovery phase of anti‑NMDAR encephalitis following immunotherapy in a young adult woman. Background:…Duration of Illness and Response to Pimavanserin in Parkinson’s Disease Psychosis: Post-Hoc Analysis of Clinical Trial Data
Objective: To examine individual responses to pimavanserin in patients with Parkinson’s disease psychosis (PDP) initiating treatment <6 vs ≥6 months and <12 vs ≥12 months…Atypical Psychosis in Parkinson Disease: A Retrospective Study on 24-Hour Continuous Subcutaneous Infusion Foslevodopa/Foscarbidopa Therapy
Objective: This study aims to identify clinical predictors of continuous subcutaneous infusion (CSCI)-induced psychosis to understand its potential mechanisms and evaluate predictive measures for its…Demographic Features, QTc Interval and Psychosis in Military Veterans with Parkinson’s disease (PD)
Objective: To compare certain key demographic features and QTc intervals in groups of PD military Veterans with and without psychosis. Background: Psychosis is a disabling…Refining the International Parkinson and Movement Disorder Society Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS): Cognitive Interview Results from an International Study
Objective: To assess the face and content validity of the International Parkinson and Movement Disorder Society Parkinson’s Disease Psychosis Rating Scale (MDS-PDPRS), a new under-developing Clinical…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 14
- Next Page »